648 A pilot study to evaluate the combination of zimberelimab, domvanalimab and etrumadenant in patients with previously treated non-small cell lung cancer (NSCLC)Anjali Rohatgi, Daniel Morgensztern, Ningying Wu et al.|Regular and Young Investigator Award Abstracts|2025Cited by 0